These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32808830)

  • 1. Pharmacological management of human respiratory syncytial virus infection.
    Kalergis AM; Soto JA; Gálvez NMS; Andrade CA; Fernandez A; Bohmwald K; Bueno SM
    Expert Opin Pharmacother; 2020 Dec; 21(18):2293-2303. PubMed ID: 32808830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapies and vaccines against the human respiratory syncytial virus.
    Rivera CA; Gómez RS; Díaz RA; Céspedes PF; Espinoza JA; González PA; Riedel CA; Bueno SM; Kalergis AM
    Expert Opin Investig Drugs; 2015; 24(12):1613-30. PubMed ID: 26457559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory Syncytial Virus: pathology, therapeutic drugs and prophylaxis.
    Gomez RS; Guisle-Marsollier I; Bohmwald K; Bueno SM; Kalergis AM
    Immunol Lett; 2014 Nov; 162(1 Pt A):237-47. PubMed ID: 25268876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice.
    Céspedes PF; Rey-Jurado E; Espinoza JA; Rivera CA; Canedo-Marroquín G; Bueno SM; Kalergis AM
    Vaccine; 2017 Feb; 35(5):757-766. PubMed ID: 28065474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of respiratory syncytial virus infection.
    Kimpen JL
    Curr Opin Infect Dis; 2001 Jun; 14(3):323-8. PubMed ID: 11964851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory markers and therapies for the management of infant respiratory syncytial virus infection.
    Loaiza RA; Farías MA; Andrade CA; Ramírez MA; Rodriguez-Guilarte L; Muñóz JT; González PA; Bueno SM; Kalergis AM
    Expert Rev Anti Infect Ther; 2024 Aug; 22(8):631-645. PubMed ID: 39269198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.
    Empey KM; Peebles RS; Kolls JK
    Clin Infect Dis; 2010 May; 50(9):1258-67. PubMed ID: 20235830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A molecular perspective for the development of antibodies against the human respiratory syncytial virus.
    Loaiza RA; Ramírez RA; Sepúlveda-Alfaro J; Ramírez MA; Andrade CA; Soto JA; González PA; Bueno SM; Kalergis AM
    Antiviral Res; 2024 Feb; 222():105783. PubMed ID: 38145755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of antibody response during natural hRSV infection: insights for the development of new antibody-based therapies.
    Muñoz-Durango N; Pizarro-Ortega MS; Rey-Jurado E; Díaz FE; Bueno SM; Kalergis AM
    Expert Opin Investig Drugs; 2018 Sep; 27(9):721-731. PubMed ID: 30111181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine Design.
    Rey-Jurado E; Kalergis AM
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28273842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody development for preventing the human respiratory syncytial virus pathology.
    Soto JA; Gálvez NMS; Pacheco GA; Bueno SM; Kalergis AM
    Mol Med; 2020 Apr; 26(1):35. PubMed ID: 32303184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal antivirals against respiratory syncytial virus: the current therapeutic development landscape.
    Oti VB; Idris A; McMillan NAJ
    Expert Rev Anti Infect Ther; 2024 Aug; 22(8):647-657. PubMed ID: 38973346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of Fcγ receptors to human respiratory syncytial virus pathogenesis and the impairment of T-cell activation by dendritic cells.
    Gómez RS; Ramirez BA; Céspedes PF; Cautivo KM; Riquelme SA; Prado CE; González PA; Kalergis AM
    Immunology; 2016 Jan; 147(1):55-72. PubMed ID: 26451966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Respiratory syncytial virus].
    Seidenberg J
    Internist (Berl); 2019 Nov; 60(11):1146-1150. PubMed ID: 31486858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory syncytial virus: prospects for new and emerging therapeutics.
    Jorquera PA; Tripp RA
    Expert Rev Respir Med; 2017 Aug; 11(8):609-615. PubMed ID: 28574729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory syncytial virus disease: prevention and treatment.
    Chu HY; Englund JA
    Curr Top Microbiol Immunol; 2013; 372():235-58. PubMed ID: 24362693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ongoing developments in RSV prophylaxis: a clinician's analysis.
    Rezaee F; Linfield DT; Harford TJ; Piedimonte G
    Curr Opin Virol; 2017 Jun; 24():70-78. PubMed ID: 28500974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory syncytial virus infections: characteristics and treatment.
    Chidgey SM; Broadley KJ
    J Pharm Pharmacol; 2005 Nov; 57(11):1371-81. PubMed ID: 16259768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus.
    Rey-Jurado E; Soto J; Gálvez N; Kalergis AM
    Hum Vaccin Immunother; 2017 Sep; 13(9):2092-2097. PubMed ID: 28598702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.